# Cancer Immunotherapy Domain: Advanced Medicine · 288 papers indexed · newest 2026-10-27 Immune checkpoint inhibitors, CAR-T and TIL cell therapies including solid tumors, T-cell engagers and bispecifics, and antibody-drug conjugates. Key concepts: immunotherapy, CAR-T, checkpoint inhibitor ## Most influential - **[Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review](https://space-kitty.com/papers/doi:10.1159/000455014)**. Rimda Wanchoo, Sabine Karam, Nupur N. Uppal et al. · 2017 · American Journal of Nephrology (doi:10.1159/000455014 · 15,256 citations). Source: - **[Hepatocellular carcinoma](https://space-kitty.com/papers/doi:10.1038/s41572-020-00240-3)**. Josep Maria Llovet, Robin Kate Kelley, Augusto Villanueva et al. · 2021 · Nature Reviews Disease Primers (doi:10.1038/s41572-020-00240-3 · 7,050 citations). Source: - **[Tumor mutational load predicts survival after immunotherapy across multiple cancer types](https://space-kitty.com/papers/doi:10.1038/s41588-018-0312-8)**. Robert M. Samstein, Chung‐Han Lee, Alexander Noor Shoushtari et al. · 2019 · Nature Genetics (doi:10.1038/s41588-018-0312-8 · 4,069 citations). Source: - **[Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden](https://space-kitty.com/papers/doi:10.1186/s13073-017-0424-2)**. Zachary Rockow Chalmers, Caitlin F. Connelly, David A. Fabrizio et al. · 2017 · Genome Medicine (doi:10.1186/s13073-017-0424-2 · 3,517 citations). Source: > BACKGROUND: High tumor mutational burden (TMB) is an emerging biomarker of sensitivity to immune checkpoint inhibitors and has been shown to be more significantly associated with response to PD-1 and PD-L1 blockade immunotherapy than PD-1 or PD-L1 expression, as measured by immunohistochemistry (IHC). The distribution of TMB and the subset of patients with high TMB has not been well characterized in the majority of cancer types. METHODS: In this study, we compare TMB measured by a targeted comprehensive genomic profiling (CGP) assay to TMB measured by exome sequencing and simulate the expected… > _Abstract excerpt by Zachary Rockow Chalmers et al., CC-BY, https://doi.org/10.1186/s13073-017-0424-2; truncated._ - **[The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications](https://space-kitty.com/papers/doi:10.1038/s41423-020-0488-6)**. Yuanyuan Zhang, Zemin Zhang · 2020 · Cellular and Molecular Immunology (doi:10.1038/s41423-020-0488-6 · 2,817 citations). Source: > Immunotherapy has revolutionized cancer treatment and rejuvenated the field of tumor immunology. Several types of immunotherapy, including adoptive cell transfer (ACT) and immune checkpoint inhibitors (ICIs), have obtained durable clinical responses, but their efficacies vary, and only subsets of cancer patients can benefit from them. Immune infiltrates in the tumor microenvironment (TME) have been shown to play a key role in tumor development and will affect the clinical outcomes of cancer patients. Comprehensive profiling of tumor-infiltrating immune cells would shed light on the mechanisms … > _Abstract excerpt by Yuanyuan Zhang et al., CC-BY, https://doi.org/10.1038/s41423-020-0488-6; truncated._ - **[Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease](https://space-kitty.com/papers/doi:10.1038/nrclinonc.2016.66)**. Giampaolo Bianchini, Justin Micah Balko, Ingrid A. Mayer et al. · 2016 · Nature Reviews Clinical Oncology (doi:10.1038/nrclinonc.2016.66 · 3,073 citations). Source: - **[Antibody drug conjugate: the "biological missile" for targeted cancer therapy](https://space-kitty.com/papers/doi:10.1038/s41392-022-00947-7)**. Fu Z, Li S, Han S et al. · 2022 · Signal transduction and targeted therapy (doi:10.1038/s41392-022-00947-7 · 1,271 citations). Source: > Antibody-drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs) covalently attached to a cytotoxic drug via a chemical linker. It combines both the advantages of highly specific targeting ability and highly potent killing effect to achieve accurate and efficient elimination of cancer cells, which has become one of the hotspots for the research and development of anticancer drugs. Since the first ADC, Mylotarg ® (gemtuzumab ozogamicin), was approved in 2000 by the US Food and Drug Administration (FDA), there have been 14 ADCs received market approval so far worldwide. Moreov… > _Abstract excerpt by Fu Z et al., CC-BY, https://doi.org/10.1038/s41392-022-00947-7; truncated._ - **[Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group](https://space-kitty.com/papers/doi:10.1186/s40425-017-0300-z)**. on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Igor J. Puzanov, Adi K. Diab et al. · 2017 · Journal for ImmunoTherapy of Cancer (doi:10.1186/s40425-017-0300-z · 1,992 citations). Source: > Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse events (irAEs). Many of these are driven by the same immunologic mechanisms responsible for the drugs' therapeutic effects, namely blockade of inhibitory mechanisms that suppress the immune system and protect body tissues from an unconstrained acute or chronic immune response. Skin, gut, endocrine, lung and musculoskeletal irAEs are relatively commo… > _Abstract excerpt by on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group et al., CC-BY, https://doi.org/10.1186/s40425-017-0300-z; truncated._ - **[Immune checkpoint inhibitors: recent progress and potential biomarkers](https://space-kitty.com/papers/doi:10.1038/s12276-018-0191-1)**. Darvin P, Toor SM, Sasidharan Nair V et al. · 2018 · Experimental & molecular medicine (doi:10.1038/s12276-018-0191-1 · 1,602 citations). Source: > Cancer growth and progression are associated with immune suppression. Cancer cells have the ability to activate different immune checkpoint pathways that harbor immunosuppressive functions. Monoclonal antibodies that target immune checkpoints provided an immense breakthrough in cancer therapeutics. Among the immune checkpoint inhibitors, PD-1/PD-L1 and CTLA-4 inhibitors showed promising therapeutic outcomes, and some have been approved for certain cancer treatments, while others are under clinical trials. Recent reports have shown that patients with various malignancies benefit from immune che… > _Abstract excerpt by Darvin P et al., CC-BY, https://doi.org/10.1038/s12276-018-0191-1; truncated._ - **[Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer](https://space-kitty.com/papers/doi:10.1038/nature23003)**. Uğur Şahin, Evelyna Derhovanessian, Matthias Miller et al. · 2017 · Nature (doi:10.1038/nature23003 · 2,485 citations). Source: - **[The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy](https://space-kitty.com/papers/doi:10.1038/s41568-019-0116-x)**. Jonathan J. Havel, Diego Chowell, Timothy An-thy Chan · 2019 · Nature reviews. Cancer (doi:10.1038/s41568-019-0116-x · 2,285 citations). Source: - **[Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance](https://space-kitty.com/papers/doi:10.1146/annurev-pathol-042020-042741)**. Sreya Bagchi, Robert T. Yuan, Edgar G. Engleman · 2020 · Annual Review of Pathology Mechanisms of Disease (doi:10.1146/annurev-pathol-042020-042741 · 2,188 citations). Source: - **[Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy](https://space-kitty.com/papers/doi:10.1038/s41392-022-01046-3)**. Weitong Gao, Yuqin Wang, Yang Zhou et al. · 2022 · Signal Transduction and Targeted Therapy (doi:10.1038/s41392-022-01046-3 · 1,052 citations). Source: > In recent years, immunotherapy represented by immune checkpoint inhibitors (ICIs) has led to unprecedented breakthroughs in cancer treatment. However, the fact that many tumors respond poorly or even not to ICIs, partly caused by the absence of tumor-infiltrating lymphocytes (TILs), significantly limits the application of ICIs. Converting these immune "cold" tumors into "hot" tumors that may respond to ICIs is an unsolved question in cancer immunotherapy. Since it is a general characteristic of cancers to resist apoptosis, induction of non-apoptotic regulated cell death (RCD) is emerging as a … > _Abstract excerpt by Weitong Gao et al., CC-BY, https://doi.org/10.1038/s41392-022-01046-3; truncated._ - **[Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence](https://space-kitty.com/papers/doi:10.3390/cancers12030738)**. Raju Kumar Vaddepally, Prakash Kharel, Ramesh Kumar Pandey et al. · 2020 · Cancers (doi:10.3390/cancers12030738 · 1,198 citations). Source: > Cancer is associated with higher morbidity and mortality and is the second leading cause of death in the US. Further, in some nations, cancer has overtaken heart disease as the leading cause of mortality. Identification of molecular mechanisms by which cancerous cells evade T cell-mediated cytotoxic damage has led to the modern era of immunotherapy in cancer treatment. Agents that release these immune brakes have shown activity to recover dysfunctional T cells and regress various cancer. Both cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and Programmed Death-1 (PD-1) play their role as … > _Abstract excerpt by Raju Kumar Vaddepally et al., CC-BY, https://doi.org/10.3390/cancers12030738; truncated._ - **[Macrophages as tools and targets in cancer therapy](https://space-kitty.com/papers/doi:10.1038/s41573-022-00520-5)**. Alberto Mantovani, Paola Allavena, Federica Marchesi et al. · 2022 · Nature Reviews Drug Discovery (doi:10.1038/s41573-022-00520-5 · 1,806 citations). Source: ## Newest - **[The METAMAX Study: MT027 Allogeneic CAR-T for Brain Metastases From Advanced Solid Tumors](https://space-kitty.com/papers/nct:NCT07897799)**. T-MAXIMUM Pharmaceutical Inc · 2026 · ClinicalTrials.gov (NCT07897799). Source: - **[Blocking aryl hydrocarbon receptor remodels myeloid-T cell crosstalk and enhances anti-PD-1 response in the tumor microenvironment](https://space-kitty.com/papers/doi:10.1186/s40164-026-00843-8)**. Kim DK, Baek S, Kim Y et al. · 2026 · Experimental hematology & oncology (doi:10.1186/s40164-026-00843-8). Source: - **[Neuronal intermediate filament neurologic autoimmunity in a patient with Merkel cell carcinoma receiving pembrolizumab](https://space-kitty.com/papers/doi:10.1007/s10072-026-09500-8)**. Hijazi A, Guleryuz S, Walshauser MA et al. · 2026 · Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (doi:10.1007/s10072-026-09500-8). Source: - **[Extracorporeal photopheresis for the treatment of steroid-refractory immune related adverse events from immune checkpoint inhibitor therapy: a multi-center phase Ib/II clinical trial](https://space-kitty.com/papers/doi:10.1038/s41467-026-78897-9)**. Riemer R, Braun LM, Giesler S et al. · 2026 · Nature communications (doi:10.1038/s41467-026-78897-9). Source: - **[Dysregulation of the Hippo pathway enhances PD-L2 transcription to promote immune evasion in head and neck squamous cell carcinoma](https://space-kitty.com/papers/doi:10.1038/s42003-026-11092-0)**. Ando T, Okamoto K, Sato K et al. · 2026 · Communications biology (doi:10.1038/s42003-026-11092-0). Source: - **[Cell-Based Assay Development and Standardization for Antibody-Drug Conjugates](https://space-kitty.com/papers/doi:10.3390/biotech15040096)**. Sun D, Hsu A, Long H et al. · 2026 · Biotech (Basel (Switzerland)) (doi:10.3390/biotech15040096). Source: - **[Immune Checkpoint Inhibitor-Associated Pneumonitis in Patients Treated for Metastatic Renal Cell Carcinoma](https://space-kitty.com/papers/doi:10.3390/curroncol33100616)**. Masur J, Mullapudi A, Ali S et al. · 2026 · Current oncology (Toronto, Ont.) (doi:10.3390/curroncol33100616). Source: - **[From Dysbiosis to Symbiosis: Using the Gut Microbiome to Improve Cancer Outcomes](https://space-kitty.com/papers/doi:10.3390/medsci14060669)**. Nassar SA · 2026 · Medical sciences (Basel, Switzerland) (doi:10.3390/medsci14060669). Source: - **[A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer](https://space-kitty.com/papers/nct:NCT07865910)**. Shanghai Henlius Biotech · 2026 · ClinicalTrials.gov (NCT07865910). Source: - **[Patient-Reported Burden and Clinical Spectrum of Rheumatic Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy in Lung Cancer: A Real-World Cohort Study](https://space-kitty.com/papers/doi:10.3390/curroncol33100603)**. Ren Z, Lu J · 2026 · Current oncology (Toronto, Ont.) (doi:10.3390/curroncol33100603). Source: ## Clinical trials - **[Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors](https://space-kitty.com/papers/nct:NCT05055908)**. Hunan Province Tumor Hospital · 2021 · ClinicalTrials.gov (NCT05055908). Source: - **[A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer](https://space-kitty.com/papers/nct:NCT07865910)**. Shanghai Henlius Biotech · 2026 · ClinicalTrials.gov (NCT07865910). Source: - **[A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia](https://space-kitty.com/papers/nct:NCT03914625)**. National Cancer Institute (NCI) · 2019 · ClinicalTrials.gov (NCT03914625). Source: - **[A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer](https://space-kitty.com/papers/nct:NCT06112379)**. AstraZeneca · 2023 · ClinicalTrials.gov (NCT06112379). Source: - **[Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy](https://space-kitty.com/papers/nct:NCT03959085)**. Children's Oncology Group · 2019 · ClinicalTrials.gov (NCT03959085). Source: - **[Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)](https://space-kitty.com/papers/nct:NCT06712316)**. BioNTech SE · 2024 · ClinicalTrials.gov (NCT06712316). Source: - **[Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017](https://space-kitty.com/papers/nct:NCT03643276)**. Martin Schrappe · 2018 · ClinicalTrials.gov (NCT03643276). Source: - **[Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery](https://space-kitty.com/papers/nct:NCT01274338)**. National Cancer Institute (NCI) · 2011 · ClinicalTrials.gov (NCT01274338). Source: --- Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.